Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil La...
-
A new therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens for sleeping sickness.
-
MicrobiotiX and WAFCIRC sign MoU and Research Collaboration Agreement in Ghana, launching clinical research to evaluate phage therapy for AMR infections.
-
Study Identifies Blood Protein Albumin as Key Defense Against Deadly fungal infection “Mucormycosis”
Los Angeles, Jan. 26, 2026 (GLOBE NEWSWIRE) -- A new international study published in Nature has identified albumin, the most abundant protein in human blood, as a powerful and previously...
-
Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Lundquist Institute (TLI) and its start-up company Vitalex Biosciences (Vitalex) are pleased to announce that the second-generation fungal...
-
Tevogen honors Board Member Dr. Curtis Patton as Yale recognizes his distinguished career, underscoring the Company’s ongoing growth.
-
WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ,...
-
The Global Virus Network issued a statement newly confirmed outbreak of Marburg virus disease in southern Ethiopia.
-
Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program...
-
MicrobiotiX and KATH sign MoU to advance clinical bacteriophage therapies against AMR·MDR and expand treatment options for patients in Africa.